https://engineering.wustl.edu/news/Pages/taber-receives-2020-lissner-award-from-asme.aspx1340Taber receives 2020 Lissner award from ASME<p>​Larry Taber, senior professor of biomedical engineering at the McKelvey School of Engineering, has been named the recipient of the 2020 H.R. Lissner Medal by the American Society of Mechanical Engineers (ASME).<br/></p><img alt="" src="/Profiles/PublishingImages/Taber_Larry.jpg?RenditionID=2" style="BORDER:0px solid;" /><p>​The prestigious Lissner Medal recognizes outstanding achievements in the field of bioengineering, including research contributions, bioengineering innovations or educational impact, as well as distinguished service with the ASME. It is the highest honor in the ASME's bioengineering division.</p><p>"When I first heard about the award, I was extremely surprised, as I didn't even know I was nominated," Taber said. "To me, it means that my research contributions have had more impact than I thought."</p><p>Taber was nominated for the award by Philip Bayly, the Lilyan & E. Lisle Hughes Professor of Mechanical Engineering and chair of the Department of Mechanical Engineering & Materials Science</p><p>"Larry's work has enabled new understanding of the changes in shape and structure that take place in the developing embryo," Bayly said. "He has inspired many other researchers, including his former students and colleagues like me, to work on the mechanics of heart and brain development."</p><p>Pat Alford, who earned a doctoral degree in biomedical engineering from Washington University in St. Louis in 2007, presented Taber with his award during a virtual recognition ceremony.</p><p>"Larry was my thesis adviser, and you could not hope for a better one," Alford said. "This award is long overdue, and I'm so happy to be the one to present it."</p><p>During the ceremony, Taber discussed his career and research interests that spanned from his undergraduate studies to his eventual retirement in 2017. An avid baseball fan, he also touched on his love for the St. Louis Cardinals.</p><p>"Larry has taught so many, so much during his time at WashU as a founding member of the Department of Biomedical Engineering," said Lori Setton, the Lucy & Stanley Lopata Distinguished Professor of Biomedical Engineering and chair of the department. "He reminds us in his Lissner Award lecture that his curiosity took him from hearts to brains to nerves to the Cardinals."</p><p>Taber came to Washington University in St. Louis in 1997 as a founding member of the Department of Biomedical Engineering. During his tenure with the university, he made history by being the first person to ever receive the Richard Skalak Award for the best paper published in the <em>Journal of Biomechanical Engineering</em> three times. Taber most recently won the award in 2015 for a paper titled "Bending of the looping heart: Differential growth revisited." He also received the award in 2004 and 2007.<br/></p>Danielle Lacey2020-06-30T05:00:00ZLarry Taber, senior professor of biomedical engineering, was recognized by the American Society of Mechanical Engineers for his contributions to the field of bioengineering.
https://engineering.wustl.edu/news/Pages/Chen-receives-$500,000-grant-to-study-new-technique-in-pediatric-brain-cancer.aspx1337Chen receives $500,000 grant to study new technique in pediatric brain cancer model<img alt="" src="/Profiles/PublishingImages/Chen_Hong_7_15_06.jpg?RenditionID=2" style="BORDER:0px solid;" /><div id="__publishingReusableFragmentIdSection"><a href="/ReusableContent/36_.000">a</a></div><p>​In Australia, brain cancer kills more children than any other disease. But it is difficult to treat without significant risks from surgical or drug treatment.</p><p>Hong Chen, assistant professor of biomedical engineering in the Washington University in St. Louis McKelvey School of Engineering and of radiation oncology in the School of Medicine, will address the need for innovative approaches to treating pediatric brain cancer with a three-year, $500,000 grant from the Charlie Teo Foundation. With the funding, she and her team plan to develop the focused ultrasound mediated intranasal (FUSIN) delivery technique to deliver drugs from the nose to the brain, bypassing the blood-brain barrier and minimizing exposure of other organs to the drug.<br/></p><p>Chen's <a href="/news/Pages/Focused-delivery-for-brain-cancers.aspx">FUSIN technique</a> uses focused ultrasound to target a specific location in the brain, then delivers microbubbles to the targeted location. Once the microbubbles arrive at the tumor, they pop, delivering the intranasally administered drug in the tissue surrounding the tumor.<br/></p><p>Specifically, Chen and her team will focus on diffuse midline gliomas, the most deadly pediatric cancer with a 100% mortality rate and a median survival rate of less than 1 year, in a large animal model. They have previously had success with the technique in a mouse model. By studying the accuracy and safety of the technique in a large animal model, they are seeking to establish the clinical translation potential of the technique into humans.</p><p> </p><SPAN ID="__publishingReusableFragment"></SPAN><p><br/></p><p> </p><p><br/></p>Beth Miller 2020-06-23T05:00:00ZHong Chen and her team will study her focused ultrasound treatment's efficacy on deadly pediatric brain cancer
https://engineering.wustl.edu/news/Pages/despite-detours-alumna-ahmad-found-her-place-in-engineering.aspx1335Despite detours, alumna Ahmad found her place in engineering <p>​Zaineb Ahmad's journey to her current position with Collins Aerospace took a few detours.<br/></p><img alt="Headshot of Zaineb Ahmad" src="/news/PublishingImages/ahmad-zaineb.jpg?RenditionID=2" style="BORDER:0px solid;" /><p>A human factors and systems engineer with the aerospace and defense company, Ahmad earned a bachelor's degree in biomedical engineering from the engineering school in 2008.<br/></p><p>"I was on the path of medicine for a long time, and while I was passionate about it at the time, going into engineering has been very fulfilling for me," Ahmad said.</p><p>So much so that after earning an undergraduate degree, Ahmad put medical school on hold to earn a master's degree in mechanical engineering from the University of Alabama at Birmingham.</p><p>"I did pursue a medical program for a short while after that, but I realized that wasn't the right fit for me," she said.</p><p>Ahmad returned to industry, working for a fellow WashU alumnus at a medical device startup and, later, as a product owner and a business analyst for a health care IT company. It wasn't until recently that she made her way into aerospace.</p><p>"I've learned that engineers can belong anywhere," Ahmad said. "Once you have those problem-solving and critical-thinking skills, you can find your way into any industry."</p><p>Ahmad has done more than just find her way; she's thrived. This year, she was awarded the Society of Women Engineers (SWE) WE Local New ELiTE (Emerging Leader in Technology and Engineering) Award.  </p><p>"This award has been a culmination of the all the different fields I've tried and industries I've worked with," Ahmad said. "This recognizes that engineering was the right choice for me, and it's definitely somewhere I belong."</p><p>Ahmad was a member of SWE as an undergraduate at WashU and currently serves as president of the Dallas SWE professional section. She credits the organization with helping her to get involved with the engineering community and to build her professional network.</p><p>"There are still times when engineering feels very, very male dominated and like you're being pushed out," she said. "It's encouraging to have these women remind you that you belong, and you're doing the right thing."</p><p>Ahmad is optimistic about the future of diversity and inclusion in the field — as long as industries remain committed to doing the work.</p><p>"I think things are getting better," she said. "Maybe only on a case-by-case basis, but it is getting better. There's definitely room for women, and we definitely see the advantages of having women serve in STEM roles, but I think we still have a way to go."<br/></p>Danielle Lacey2020-06-22T05:00:00ZZaineb Ahmad, who earned a degree in biomedical engineering, has found success as a systems engineer with an aerospace and defense company.
https://engineering.wustl.edu/news/Pages/How-an-invention-gets-out-of-the-lab-and-into-the-world.aspx1333How an invention gets out of the lab and into the world<img alt="" src="/news/PublishingImages/OTM_Feature-intro-760x909.jpg?RenditionID=9" style="BORDER:0px solid;" /><p> A researcher comes up with a great idea — software that lets you see the heart differently, a mesh that can heal wounds, a rapid test for heart attacks. So, now what?</p><p>It may seem straightforward — get the idea “out there.” But how exactly is that accomplished? At Washington University it’s through the <a href="https://otm.wustl.edu/">Office of Technology Management</a> (OTM), which guides innovators through the process of licensing intellectual property, launching startups, finding funding, filing patents and executing anything else necessary to bring an innovation to the marketplace.</p><p></p><p>“University technology can linger on the vine and die there, and it shouldn’t,” says Nichole Mercier, assistant vice chancellor and managing director of OTM. Under her leadership, OTM has sharpened its focus on customer service, connected more with innovators to find out about new discoveries, and created Quick Start Licenses that can get technology licensed in as little as 30 days.</p><p>“My vision is to define how we can pair cutting-edge university research with expertise and exceptional customer service from my office in order to create a pipeline of opportunities that can be beneficial to society,” says Mercier. Here is what happens when great ideas have a well-run innovation pipeline.<br/></p> <h3>Mapping the heart</h3><p>In summer 2015, Jon Silva, PhD ’98, associate professor of biomedical engineering in the McKelvey School of Engineering, was invited to the Microsoft campus to learn about the company’s latest tech. One item was the HoloLens, a mixed-reality headset that allows the wearer to see holographic images while still being able to observe the room around them.</p><p>“That has potential,” Jon thought and called his wife, Jennifer N. Silva, MD, associate professor of pediatrics in the School of Medicine. He asked her if it would be helpful to see the heart in three dimensions instead of the typical two when she treated patients with arrhythmia.<br/></p> <p>Jennifer was immediately enthusiastic. As a physician, she works in an electrophysiology cardiac catheterization lab. With the catheter, she maps out where the heart’s electrophysiological abnormalities are by creating two 2D images that she must then interpret to decide whether to surgically remove tissue. It can lead to a lot of mental fatigue.</p><p>“But we weren’t thinking, ‘let’s make a commercial tool,’” she recalls. “We just thought, ‘Wouldn’t it be great if we could do this?’”</p><p>The Silvas were the perfect team to tackle the project. The two met while working in the lab of biomedical engineer Yoram Rudy, the Fred Saigh Distinguished Professor of Engineering, who studies the heart. Jon was working on the data, doing computational modeling of molecules. Jen was looking at the whole heart, working on a noninvasive way to do electrocardiographic imaging — which led to the creation of the CardioInsight mapping vest (see sidebar below).</p><p>Despite both being interested in the electrophysiology of the heart, they had never found a project that dovetailed so perfectly with both their expertise.</p><p>Over winter break in 2015, Jon started working on software prototypes, which used catheter lab data to make a 3D image in the HoloLens. While gathering the data, Jennifer talked to some of her medical colleagues about the idea.</p><p>“They told me, ‘Stop talking. Go write a patent!’” Jennifer recalls. So she and Jon went to the Office of Technology Management.</p><p>The staff there helped them file a patent, using outside patent attorneys to draft the patent application. “What was exceptional about our colleagues at OTM was they taught us along the way,” Jennifer says.<br/></p><p>With OTM’s help, the Silvas learned they’d need to form a company and were introduced to early funders. They connected with the <a href="https://skandalaris.wustl.edu/">Skandalaris Center</a> and competed in <a href="https://skandalaris.wustl.edu/sc-programs/leap/">LEAP: Leadership and Entrepreneurial Acceleration Program</a>, a pitch competition that awards grants of up to $50,000 to advance university intellectual property toward commercialization. And LEAP participants get training on how to pitch investors.</p><p>Armed with their new skills, the Silva’s won that grant and several others, including funding from the Children’s Discovery Institute, which allowed them to launch their company, <a href="https://sentiar.com/">SentiAR</a>, in 2017.</p><p>The SentiAR technology is considered a class 2 medical device, more complex than sunglasses (class 1 device) and less complex than a pacemaker (class 3). It requires approval by the FDA, and the Silva’s were able to get a $2.2 million grant from the National Institutes of Health and another $2 million from Venture Fund in St. Louis to go through the approval process. After two years in summer 2019, physicians were testing the SentiAR system in the lab for the first time.</p><p>“That was so exciting,” Jon says. “And in the early returns that we’re seeing, the physicians are getting their catheters to a better place, and the data reflect they have an easier, quicker understanding of what’s going on in the heart.”</p><p>(The Silvas will discuss the development of SentiAR and their software in a <a href="https://happenings.wustl.edu/event/from_idea_to_sentiar_an_unexpected_journey_to_entrepreneurship#.XuD_hGpKhZI">virtual event on June 18</a>.)<br/></p> <p></p> <h3>Advancing wound care</h3><p>When Joe came to BJC, he’d already had an open wound on his leg for more than a year. Joe had acquired it while battling head and neck cancer when doctors harvested bone from his leg to reconstruct his jaw. Though small, the wound was a plague. He had to bandage it every day and was constantly worried about infection. He couldn’t swim with his children, and it interfered with his career as a parole officer.</p><p>BJC was his last hope. But after seven surgeries, his wound was still not healing properly.</p><p>Fortunately, down the hall from his surgeon’s office was Matthew MacEwan, MD ’08, PhD ’18, who had developed a new technology capable of treating chronic wounds. As a graduate student, MacEwan had discovered that nanoscale materials could restore damaged tissue and heal difficult wounds. He took resorbable polymers, materials capable of dissolving in a patient’s body, and built matrices of nanoscale fibers on them that served as a scaffold for native cells to grow. MacEwan’s product, <a href="https://acera-surgical.com/restrata/">Restrata Wound Matrix</a>, was ultimately used to successfully close Joe’s wound.<br/></p> <p></p><p>The discovery that led to this healing happened almost by accident. While earning his PhD in biomedical engineering at WashU, MacEwan worked next door to a lab where researchers were synthesizing various nanoparticles and nanomaterials. Intrigued, MacEwan wanted to see how they could be used in regenerative medical applications.</p><p>“That’s really what led to some of our initial discoveries around the biological potential of these nanofiber materials, and eventually the formation of the company,” MacEwan says.</p><p>In 2013, MacEwan founded <a href="https://acera-surgical.com/">Acera Surgical</a>, while he was still a graduate student. His first product was a nanoscale material designed to repair the membrane around the brain and spinal cord, Cerafix Dura Substitute, which he made in conjunction with Washington University neurosurgeons. When Cerafix was approved by the FDA in 2016, it became the first nanofabricated surgical material approved in the U.S. Using the same technology, MacEwan designed Restrata for soft-tissue repair and <a href="https://acera-surgical.com/covora/">Covora</a> for partial-thickness burns. Today, MacEwan’s nanofiber technology is being used across the country in academic, commercial and VA hospitals. The materials offer an alternative to costly animal- and human-tissue products.</p><p>MacEwan gives a great deal of credit to the university for helping him through the process of bringing his technology to market.</p><p>“WashU is an amazing ecosystem,” MacEwan says. “There are so many talented individuals who are willing and excited to help develop new ideas and find new ways to improve human health. That includes in the Office of Technology Management, where they help make innovations into businesses. I’m positive that our connection to WashU, OTM and to St. Louis was critical to the success of our business.”<br/></p> <h3>Testing a broken heart<br/></h3><p>The Office of Technology Management is not new to the university. Back in the early 1980s, Jack Ladenson, the Oree M. Carroll and Lillian B. Ladenson Professor of Clinical Chemistry, had a problem OTM helped him solve: angry clinical fellows and stressed lab techs.</p><p>Ladenson is a pathologist, and at the time the blood test (CK-MB, or creatine kinase MB isoenzyme) to determine if a patient had had a heart attack, or myocardial infarction (MI), took three hours to complete. The problem? New drugs to break up blood clots and re-establish blood flow needed to be administered within four hours of the onset of the MI.</p><p>“I’ve never seen such strained relationships between the laboratory and a clinical service,” Ladenson says. “And you couldn’t just blow it off, because it was real. It was pressure.”<br/></p><p>Ladenson set out to find a way to get faster test results. With funding from Monsanto, his lab discovered two monoclonal antibodies — antibodies from a cell line made in labs that react to the presence of selected proteins in the blood, in this case CK-MB, which is released by the heart into the blood when an MI occurs.</p><p>“It was a faster way to measure if a person had suffered a heart attack, and that speed led to a greater degree of clinical success,” Ladenson explains.</p><p>When Ladenson presented his findings to Monsanto, it filed for a patent, but then returned rights for the discovery back to the university. Ladenson wasn’t sure what to do next, so he went to the university’s Office of Technology Management, which at the time had only one full-time employee, Duke Leahey, who helped Ladenson license his discovery.</p><p>Dade (now Siemens), the first health-care company to market Ladenson’s test, also funded more research. So Ladenson kept working on an even faster test and, with help from WashU’s cardiology division, came up with two.</p><p>“That’s what makes this university,” Ladenson says. “You’re able to cross departments and work together.”<br/></p><p>One test, which detected the protein Troponin-I in the bloodstream, has become the gold standard for heart attack tests for its rapidity and accuracy and is still used today.</p><p>For Ladenson, the discoveries have led to many awards, including being named a National Academy of Inventors Fellow, the highest professional distinction accorded solely to academic inventors, as well as the inaugural Distinguished Award for Contributions to Cardiovascular Diagnostics from the International Federation for Clinical Chemistry in 2017. Further, the licensing fees he’s received for his monoclonal antibodies have allowed him to establish three endowed professorships in the School of Medicine.</p><p>And OTM has remained instrumental in helping faculty and others get their technologies to market, growing from one-person office to an office of about two dozen today.</p><p>“The cooperation with OTM was incredibly important to the success of our discoveries,” he says.<br/></p><span> <div class="cstm-section"><p>​<img data-attachment-id="399452" data-permalink="https://source.wustl.edu/2020/06/accelerating-innovation/silvas/" data-orig-file="https://source.wustl.edu/wp-content/uploads/2020/06/Silvas.jpg" data-orig-size="1200,782" data-comments-opened="0" data-image-meta="{"aperture":"5.6","credit":"Joe Angeles\/Washington Universit","camera":"Canon EOS 5D Mark IV","caption":"2020-03-02--Jon & Jennifer Silva in the atrium of Whitaker Hall on the Danforth Campus of Washington University in St. Louis.","created_timestamp":"1583160125","copyright":"\u00a9 Washington University in St. Louis","focal_length":"120","iso":"800","shutter_speed":"0.016666666666667","title":"","orientation":"1"}" data-image-title="Silvas" data-image-description="<p>Jon and Jennifer Silva are behind the business SentiAR, which is creating a better way for doctors to see heart abnormalities. Photo by Joe Angeles</p>" data-medium-file="https://source.wustl.edu/wp-content/uploads/2020/06/Silvas-300x196.jpg" data-large-file="https://source.wustl.edu/wp-content/uploads/2020/06/Silvas-1024x667.jpg" class="wp-image-399452 size-medium" src="https://source.wustl.edu/wp-content/uploads/2020/06/Silvas-300x196.jpg" alt="Jon and Jen Silva" style="border-width: 0px; caret-color: #3c3d3d; color: #3c3d3d; font-family: "source sans pro", "helvetica neue", helvetica, arial, sans-serif; font-size: 19.200000762939453px; box-sizing: inherit; width: 300px; display: block; margin: 5px;"/></p> <figcaption class="wp-caption-text" style="caret-color: #3c3d3d; font-family: "source sans pro", "helvetica neue", helvetica, arial, sans-serif; box-sizing: inherit; margin-bottom: 0px; font-size: 1rem; font-style: italic; line-height: 1.333; color: #626464; margin-top: 0.25em;">Jon and Jennifer Silva are behind the business SentiAR, which is creating a better way for doctors to see heart abnormalities. (Photo by Joe Angeles)</figcaption><figcaption class="wp-caption-text" style="caret-color: #3c3d3d; font-family: "source sans pro", "helvetica neue", helvetica, arial, sans-serif; box-sizing: inherit; margin-bottom: 0px; font-size: 1rem; font-style: italic; line-height: 1.333; color: #626464; margin-top: 0.25em;"><br/></figcaption><span><hr style="border-top-width: 1px; border-top-style: solid; border-top-color: #9e0918;"/></span><header style="text-align: center;"> <h3><br/></h3><h3>WashU Discovers</h3></header><section class="embed-body" style="caret-color: #3c3d3d; color: #3c3d3d; font-family: "source sans pro", "helvetica neue", helvetica, arial, sans-serif; box-sizing: inherit; margin: 0.5em 1rem;"> <p>Here are a some other inventions that OTM has helped bring to market.</p> <h4>Swaddle blanket</h4> <p>While working with the St. Louis medical examiner’s office, Bradley T. Thach, MD, professor emeritus of pediatrics at the School of Medicine, found that most babies who had died of sudden infant death syndrome, or SIDS, were sleeping on their stomachs, despite doctors’ warnings. Many parents found that the babies were unable to sleep on their backs. In such cases, doctors recommend swaddling, tightly wrapping the baby in a blanket to make it more comfortable, but it’s difficult to do correctly. So Thach developed a swaddle blanket that was later licensed to a juvenile products manufacturer.</p> <span><hr/></span> <p> <span style="color: #666666; font-family: "ek mukta", sans-serif; font-size: 1em; font-weight: 700;">CardioInsight mapping vest</span><br/></p> <p>Yoram Rudy, the Fred Saigh Distinguished Professor of Engineering in the McKelvey School of Engineering, spent decades of his career trying to map the human heartbeat. A culmination of his efforts was a vest he created that captures cardiac electrophysiological data. Covered with 200 electrodes, the vest records the heart’s electrical activity. When used with a special workstation, it also blends data from CT scans with its mapping information to create detailed 3D cardiac maps, helping physicians better see heart problems. The vest was acquired by Medtronic.</p> <span><hr/></span> <p> <span style="color: #666666; font-family: "ek mukta", sans-serif; font-size: 1em; font-weight: 700;">Blood test for Alzheimer’s</span><br/></p> <section> <p>Started in 2007, C2N Diagnostics uses a mass spectrometry platform to detect two forms of amyloid protein in blood. The ratio of these proteins in the blood can indicate Alzheimer’s. The doctors behind the tests and company are David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor of Neurology in the School of Medicine, and Randy Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology and director of the Dominantly Inherited Alzheimer Network Trials Unit, both in the School of Medicine. “I think [this test is] going to be a game-changer for all of us,” says Holtzman, “in terms of identifying people [with Alzheimer’s] who could benefit from clinical trials.”<br/></p> <span><hr/></span> <p> <span style="color: #666666; font-family: "ek mukta", sans-serif; font-size: 1em; font-weight: 700;">Clubfoot device</span><br/></p></section><section> <p>Kids with a clubfoot, a birth defect where the foot is turned toward the body, often use a brace to correct the condition and avoid extensive surgery. The problem? The traditional club foot braces cause skin blisters and are uncomfortable, so parents don’t use them as often as they are prescribed. Matthew B. Dobbs, MD, the Dr. Asa C. and Mrs. Dorothy W. Jones Professor of Orthopedic Surgery, developed a new brace that is soft and custom-molded. Testing on patients showed that compliance increased and the kids could be more active, something restricted by the traditional brace.<br/></p> <span><hr/></span> <p> <span style="color: #666666; font-family: "ek mukta", sans-serif; font-size: 1em; font-weight: 700;">Bolstering the financial industry</span><br/></p></section><section> <p>Four professors, a mix of current and former faculty at the McKelvey School of Engineering, are reshaping the financial industry with their company Exegy. It provides technology and managed services to financial-services firms. For instance, Exegy’s newest hardware-based trading platform, Xero, can execute trading algorithms in less than a microsecond. The professors, who started Exegy in the early 2000s, also created the website Signum, which uses real-time trading signals to help investment bankers make smarter choices and save money.<br/></p></section></section></div></span>Rosalind Earlyhttps://source.wustl.edu/2020/06/accelerating-innovation/2020-06-16T05:00:00Z​The Office of Technology Management helps move ideas out of the lab and into the marketplace.<p>​The Office of Technology Management helps move ideas out of the lab and into the marketplace.<br/></p>
https://engineering.wustl.edu/news/Pages/Machine-learning-imaging-technique-provide-better-insight-into-colorectal-tissue.aspx1331Machine learning, imaging technique provide better insight into colorectal tissue<img alt="" src="/news/PublishingImages/journal%20of%20biophotonics%20colorectal%20tissue.jpg?RenditionID=11" style="BORDER:0px solid;" /><div id="__publishingReusableFragmentIdSection"><a href="/ReusableContent/36_.000">a</a></div><p>​A team of biomedical engineers and colorectal surgeons at Washington University in St. Louis has used a new machine-learning algorithm coupled with a new hand-held multi-wavelength imaging device to better differentiate abnormal from normal colorectal tissues. The method may improve colorectal cancer screening, surveillance and treatment decision-making in the future.<br/></p><p>Definitive screening for colon cancer and post-treatment rectal cancer surveillance currently relies on visual inspection of tissue with an endoscopic camera. This technique cannot detect subsurface lesions and lacks quantitative measures, limiting its accuracy. To better detect cancer in early stages of growth or recurrence, clinicians need improved imaging modalities.  <br/></p><p>Shuying Li and Yifeng Zeng, both doctoral students in the lab of Quing Zhu, professor of biomedical engineering in the McKelvey School of Engineering, and William C. Chapman Jr., MD, a general surgery resident working with Matthew Mutch, MD, chief of colorectal surgery at the School of Medicine, used the new hand-held multiwavelength spatial frequency domain imaging (SFDI probe to image resected colon tissue from 16 human patients. A novel AdaBoost machine-learning algorithm using tissue absorption and scattering features was then developed for automatic tissue classification. Using a total of 88 regions of interest (44 normal areas, 14 benign polyps and 30 cancer areas) collected in this study, the authors demonstrated excellent model classification. A superior area under the receiver operating characteristic curve of 0.95 was achieved for distinguishing between normal and abnormal colorectal tissue, Zhu said.  <br/></p><p>The results were published in the June issue of the <em>Journal of Biophotonics</em> with an image featured on the inside cover. The team is the first to use an AdaBoost-based multi-wavelength SFDI system to classify colorectal tissues, including normal, cancerous, and benign polyps. Potential applications of this technology include incorporation with traditional flexible endoscopy devices or creation of novel rigid proctoscopy platform.<br/></p><SPAN ID="__publishingReusableFragment"></SPAN><p>The study was funded by the National Institutes of Health (R01 CA228047, R01 EB002136 and T32CA009621).<br/></p><p>Li S, Zeng Y, Chapman W, Erfanzadeh M, Nandy S, Mutch M, Zhu Q. Adaptive Boosting (AdaBoost)‐based multiwavelength spatial frequency domain imaging and characterization for ex vivo human colorectal tissue assessment. Journal of Biophotonics, June 2020. Published online March 3, 2020. <a href="https://doi.org/10.1002/jbio.201960241">https://doi.org/10.1002/jbio.201960241</a><br/></p>2020-06-15T05:00:00ZA team from McKelvey Engineering and the School of Medicine has developed a new method to detect cancerous tissue in the colon by combining machine learning and imaging.

​​​

VIEW ALL BME NEWS